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ABSTRACT: There is accumulating evidence that some biochemical pathways observ­
able by magnetic resonance spectroscopy, e.g., citrate acid and phospholipid metabolism, 
are altered in human prostate cancer. Four well-established human prostate cancer cell lines 
were therefore studied with magnetic resonance spectroscopy to compare differences in 
metabolic content with tumor biological behavior, Herein we demonstrate that, although 
each cell line has its own metabolic profile, relative creatine and citrate levels can be used to 
discriminate the androgen-dependent LNCaP cell line from the androgen-independent DU- 
145, TSU, and PC-3 cell lines* © 1995 Wiley-Liss, Inc,
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INTRODUCTION
The recent development and clinical introduction 
of transrectal probes not only improved the quality of 
magnetic resonance imaging (MRI) of the human 
prostate but also made this organ accessible to mag­
netic resonance spectroscopy (MRS) [1-4], Transrec­
tal MRI and MRS, basically employing the same in­
strumental setup, are potential powerful noninvasive 
methods for monitoring the diseased prostate, first, 
to identify with MRI the suspected lesion, and sec­
ondly, to monitor with MRS the metabolism of this 
lesion. Changes in various metabolic pathways asso­
ciated with several cancers have been reported [5-7], 
For prostate cancer, metabolic derangements might 
provide markers that improve diagnosis and allow 
more accurate prediction of its clinical behavior. In 
vitro and in vivo studies employing 31P, 1H, and 13C 
MRS have shown that differences in the metabolic 
content of human prostate tissue samples correlated 
with tumor grade [3,4/8-14], Moreover, for the Dun­
ning R-3327 rat tumor model, it has been demon­
strated that the relative levels of phosphocreatine, 
glycerophosphorylglycerol, glycerophosphoethano- 
lamine, and glycerophosphocholine, obtained by aH 
and 31P MRS, can be used to differentiate sublines by
differentiation grade, androgen sensitivity, and met­
astatic capacity [15,16].
However, interpretations of differences in MRS 
spectra between human prostate tissues with differ­
ent biological behavior are hampered by tissue het­
erogeneity and the lack of a complete understanding 
of biochemical pathways. MRS examinations of well- 
defined human model systems are therefore needed 
to allow correlations between metabolic patterns and 
biological behavior. For this reason, studies of human 
prostate (cancer) cell strains are of value. Yacoe et al. 
[17] investigated cell strains derived from human 
prostates to investigate whether 1H MRS could reli­
ably distinguish normal prostate epithelium from 
prostate cancer.17 In the present study we attempted 
to identify differences in metabolites which correlated 
with different biological behavior, e.g., androgen re­
sponsiveness and morphology, in human prostate 
cancer. Four well-established human prostate cancer
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TABLE I. Characteristics of the Four Human Prostate Cancer Cell Lines Used
Cell line
LNCaP15
DU-14516
PC-317
TSU-PR118
Origin
Lymph node
Brain
Bone
Lymph node
Histoiogy of 
original tumor
Moderately different 
Poorly different 
Poorly different 
Poorly different
Doubling 
time (hr)
50.1 ± 8 
28.7 ±  2.9
35.2 ± 6.7 
26.4 ± 4 . 5
Androgen
responsiveness
+
PSA-
producing
cell lines were characterized with in vitro proton 
MRS, and metabolic differences were correlated with 
their biological behavior.
MATERIALS AND METHODS
Tumor Cell Lines
Four established human prostatic carcinoma cell 
lines, PC-3, DU-145, TSU-Prl, and LNCaP, were 
used in this study, [18-21]. The characteristics of the 
four cell lines are summarized in Table I. Cells were 
maintained in RPMI 1640 culture medium (Life Sci­
ence, Breda, The Netherlands) supplemented with 
10% fetal calf serum, 2 mM L-glutamine, 100 IU/ml 
penicillin, 100 (JLg/ml streptomycin, and 250 nM dexa- 
methasone at 37°C in 6% C 0 2 at 99% relative hu­
midity.
Preparation of Tissue Extracts
After reaching a confluency of 70-80%, cells were 
harvested for perchloric acid (PCA) extraction as de­
scribed previously [14], In short, single-cell suspen­
sions were obtained by trypsinization (0.25% trypsin/
0.1% EDTA) and immediately washed three times 
with ice cold 0.9% NaCl to remove all medium com­
ponents. The total number of cells varied between 
4-6  X 106 cells. Viability, as determined by the try­
pan blue dye exclusion test, was always ^95%. After 
centrifugation of the single-cell suspension, the cell 
pellet was frozen in liquid nitrogen and stored at 
-80°C until time of extraction.
The cell pellet was transferred into an all-glass ho- 
mogenizer, and 4 ml ice-cold 0.25 M PCA were added 
dropwise. Cell homogenization was achieved at 
-80°C in approximately 30 min. After centrifugation 
(12,000 g, 15 min, 4°C) of the cell extract, the pellet 
was discarded and the pH of the supernatant was 
immediately adjusted to 7.5 with 2.5 M KOH. The 
PCA precipitate was centrifuged (12,000 g, 15 min, 
4°C), and the supernatant was passed through a 
Chelex sample preparation disc (Bio-Rad Laboraties, 
Richmond, VA) and lyophilized. Lyophilizates were
dissolved in 500 \ú 40 mM potassiumphosphate, pH 
7.0. The pH was corrected to pH 6.90-7.10 if neces­
sary by addition of HC1 or KOH. The samples were 
lyophilizated again and stored at -20°C.
Three-ml samples of culture media of all prostate 
cancer cell lines investigated were lyophilizated and 
stored at — 20°C,
Just before the lH  MRS measurements, the lyo- 
phüizate was carefully thawed and dissolved in 500 
|xl D20  containing 1.6 mM 3-(trimethylsilyl) propi­
onic acid-d4 sodium salt (TSP).
*H NMR Measurements
2H NMR spectra were acquired on a 500 MHz spec­
trometer (Bruker AM500) and were recorded with a 
standard 5 mm aH NMR probe. The spectra were 
recorded employing a 45° flip angle (6 fjis) and a 7.28 
sec pulse repetition time. The resonance of H20  was 
suppressed by low-power continuous wave presatu­
ration. For the spectrum of each PCA-extracted cell 
sample, 900 scans were accumulated. The chemical 
shifts were referenced with respect to the chemical 
shift position of the TSP resonance.
XH NMR spectra were further evaluated employ­
ing the NMR1 package (New Methods Research, Inc., 
Last Syracuse, NY) on a SUN Sparc station 330 (Sun 
Microsystems, Inc., Mountain View, CA). Free in­
duction decays (FIDs) were Fourier transformed after 
zero-filling from 16 K to 32 K and after the application 
of a Lorentzian to Gaussian transformation filter. The 
spectra were semiautomatically fitted to Gaussian 
lineshape model functions. Relative resonance inte­
grals of proton metabolites of interest are expressed 
as ratios to the integral resonance of TSP.
Statistical Analyses
Differences in ratios of metabolites between the 
different cell lines were investigated by the Wilcoxons 
rank test. Due to multiple testing, P<0.01 was con­
sidered as statistically significant.
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Fig. I. In vitro 'H MR spectrum with peak assignments of PCA extract of LNCaP human prostate 
cancer cell line.
RESULTS 
PCA-Extracted Cell Lines
MR spectra of PCA extracts of four human prostate 
cancer cell lines were recorded, and for each cell line 
at least five different passages were investigated. A 
500 MHz proton MR spectrum of a PCA extract of the 
LNCaP cell line, with two expanded parts, is shown 
in Figure 1. Resonances of some main metabolites 
could be identified with data from the literature [14, 
2 2 ].
For each compound, the best resolved reso­
nance^) were selected for quantitation purposes. Ta­
ble II lists relative peak area integral ratios involving 
the doublet of the CH3 group of lactate (Lac) at 1.33 
ppm, the doublet of the CH3 group of alanine (Ala) 
at 1.49 ppm, the quartet of the CH2 group of citrate 
(Cit) at 2.54 ppm, the singlet of the CH3 group of 
(phospho)creatine at 3.04/3.05 ppm, singlets of the 
CH3 groups of phosphocholine (PC) and choline 
(Choi) at 3.23 and 3.22 ppm respectively, the triplet of 
the CH2 group of taurine (Tau) at 3.42 ppm, the sin­
glet of the CH2 group of glycine (Gly) at 3.59 ppm, 
and the triplet of the CH group of inositol (Ino) at 3.63 
ppm.
Several differences were found among MRS spec­
tra of the PCA-extracted human cell lines.
The first prominent observation was of the rela­
tively high amount of total creatine (TCr = PCr + Cr) 
in the PCA extracts of LNCaP cells (Table II). The 
TCr/TPS ratio was significantly higher for the LNCaP 
cells samples when compared with the other three 
cell lines (P <  0.01).
Secondly, citrate resonances were absent in the 
MR spectra of PCA extracts of the PC-3, DU-145, and 
TSU cell lines, whereas in only one of the five sam­
ples of the LNCaP cell line could citrate be detected in 
the MR spectra. Since citrate can rapidly diffuse from 
the prostate cell into the culture media, all media 
were also spectroscopically examined. 2H MR spectra 
of the culture media of the LNCaP cells showed cit­
rate resonances, whereas in all the media of the other 
three cell lines no citrate resonances were detected
(Kg. 2).
Finally, several differences in metabolic content of 
PCA extracts of DU-145, TSU, and PC-3 cells were 
found. The relative amount of taurine was signifi­
cantly higher for the DU-145 PCA cell extracts when 
compared with the PC-3 and TSU cell extracts (all 
P<0.01). PC-3 and TSU cell extracts differed signifi­
cantly from each other for inositol and creatine con­
tent, whereas the creatine content of DU-145 PCA 
extracts was also different from that of TSU PCA ex­
tracts (P<0.01, Table II).
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TABLE II. Mean of Metabolite Ratios (Range Between Parentheses) of Four Human
Prostate Cancer Cell Lines
LNCaP DU-145 TSU-PR1 PC-3
Iac/tsp 94 (18-169) 34 (11-67) 25 (14-46) 12 (6-56)
Ala/tsp 84 (18-164) 11 (7-23) 6 (4-19) 5 (1-9)
Citr/tsp 0 (0-72) 0 0 0
TCr/tsp 60 (36-132) 9 (2-11) 0 10 (3-37)
Chol/tsp 40 (18-69) 12 (9-23) 22 (15-26) 16 (7-56)
PChol/tsp 6 (3-9) 5 (4-9) 4 (0-7) 3 (1-10)
Ino/tsp 0 (0-140) 156 (6-406) 0 (0-20) 44 (21-53)
Tau/tsp 11 (0-43) 84 (20-224) 0 (0-5) 0 (0-13)
Gly/tsp 48 (0-107) 7 (0-13) 5 (0-9) 6 (3-10)
/
Fig. 2. In vitro ‘H MR spectrum of 3 ml culture medium of LNCaP human prostate cancer cell line. 
Citrate resonances are indicated.
DISCUSSION
Prostate tumors present sharp interindividual vari­
ations in biological behavior and response to therapy. 
At least 20-25% of the patients where hormonal 
treatment is the first choice therapy will not react, 
and an equal percentage become resistant to the treat- 
ment within 2 years [23,24]. Therefore, new diagnos­
tic methods able to predict more accurately the bio­
logical behavior of the tumor are needed, since these 
may lead to a better basis for individual treatment. 
Several in vitro MRS studies have suggested a possi­
ble role for this noninvasive technique for improving 
diagnosis of prostate cancer [10-15]. Moreover, cor­
relations were found for several metabolites and for 
the biological behavior of Dunning R-3327 rat pros­
tate tumor sublines. In this study, four well-charac­
terized human prostate cancer cell lines were studied 
with XH MRS to substantiate these findings. An in 
vitro approach was chosen because *H MRS of bio­
logical material may produce complex spectra, which 
are difficult to resolve in vivo. Assignments for the 
same main metabolites were made as found earlier 
for human prostate cancer [14].
In this panel of PCA-extracted human prostate 
cancer cell lines, the relative level of total creatine was 
found to be significantly increased for the hormone- 
sensitive LNCaP cell line compared to the three hor- 
mone-nonresponsive ones. This suggests a correla­
tion for hormone sensitivity and the creatine content 
of the tumor. Vigneron et al. [16] found by in vivo 31P 
MRS, an increased PCr/ATP ratio in one hormone- 
sensitive Dunning tumor subline when compared to 
one hormone-insensitive subline. Androgen depriva­
tion (orchiectomy) resulted in a significant decrease 
of this ratio [16]. However, in a recent in vitro MRS 
study, where three different hormone-sensitive and 
four different hormone-insensitive Dunning sublines 
were investigated, no specific correlation for hor-
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mortal sensitivity with relative metabolite levels could 
be made [15]. A correlation of increased PCr concen­
tration and hormone sensitivity has also been sug­
gested for rat breast cancer [25]. Creatine levels can 
presently be detected in 1H MR spectra recorded with 
transrectal probes; hence, in vivo human MRS stud­
ies  can now test the relevance of these in vitro obser­
vations [26].
Previous biochemical and MRS studies have sug­
gested that the metabolism of citrate may be altered 
in  prostate cancer [12-14,27-30]. Citrate is a secretory 
product of the prostate, and its production and se­
cretion are under androgenic control [28]. Testoster­
one stimulates the net citrate production and might 
also play an role in citrate secretion [28]. Normally 
citrate is present in human prostate tissue in high 
concentrations [27,28,30]. In culture, however, citrate 
can rapidly diffuse from the prostate cell in the cul­
ture media [27]. It is therefore obligatory to measure 
both citrate levels in prostate (cancer) cells, and in 
their culture media in studies with cultured prostate 
(cancer) cells. In the present study, citrate resonances 
were absent in the MR spectra of PCA extracts of DU 
145, PC-3, and TSU cells, and in their culture media. 
Kurhanewicz et al. [12] have already shown that cit­
rate signals could not be observed in ^  MR spectra 
of DU-145 xenografts, either in vivo or in PCA ex­
tracts. In contrast, in one of the five LNCaP extracts, 
an MRS-detectable level of citrate was found, and all 
the media of LNCaP cells showed citrate resonances 
in the MR spectra, suggesting that the hormone-de­
pendent LNCaP cells have a higher relative level of 
citrate as compared to the other three hormone-in­
sensitive cell lines. Earlier studies already suggested 
that citrate is reduced in early prostate cancer and 
nearly absent in advanced disease, both of which are 
known to have only a small portion of hormone-sen­
sitive cells [28-30]. Possibly there is a difference in 
citrate content between hormone-responsive and 
-nonresponsive prostate cancers. Our present find­
ings seem to fit well with this hypothesis and the 
aforementioned studies. However, further in vivo 
MRS studies should be performed to compare the 
citrate concentrations in tumors of patients which are 
escaped from hormonal treatment with patients who 
do respond well, to validate this finding.
Finally, each prostate cancer cell line has its own 
metabolic fingerprint, i.e., several differences in met­
abolic content were found irrespective of their biolog­
ical behavior. The most striking difference was the 
high taurine content of the DU-145 cell extracts as 
compared to both the PC-3 and the TSU cell extracts. 
Kurhanewicz et al. [12] also showed large taurine res­
onances in the in vivo and in vitro XH MRS spectra of 
the DU-145 tumor. The difference in taurine content
might be explained by differences in origin of the 
metastasis [18-21].
In conclusion, this MRS study of PCA extracts of 
four human prostate cancer cell lines demonstrates 
that, although each cell line has its own metabolic 
fingerprint, the total creatine/tsp and citrate/tsp ratios 
can be used to discriminate the androgen-dependent 
LNCaP cell line from the other androgen-indepen­
dent cell lines. The extrapolation of these findings to 
the clinic will not be so easy. Clinical MRS studies 
with transrectal probes are ongoing, but are compli­
cated by several difficulties. The minimum volumes 
(voxels) within the prostate which can be measured 
with transrectal MRS are relatively large. Heteroge­
neity of the measured lesion, i.e., contamination of 
the cancer with normal prostate tissue and/or BPH, 
cannot be excluded. Smaller volumes and spectro­
scopic imaging methods will probably solve these 
problems. Secondly, a proper absolute quantification 
of the metabolites measured with in vivo MRS is still 
not possible.
The question remains as to whether MRS will be 
clinically applicable in the detection and staging of 
prostate cancer. Our results suggest that MRS might 
possibly play a role in the identification of hormone- 
responsive prostate cancers.
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